KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study.

Yasar Torres-Yaghi, Lambros Chrones, Victor Abler, Greg Brunson

BMC Neurol 25(1) 479

PMID41286676
PMCIDPMC12642364
DOI10.1186/s12883-025-04496-8
发表日期2025-11-25
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: Pimavanserin is approved by the US Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease. We analyzed the effect of pimavanserin on psychosis in patients with Lewy body dementia, including Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB), from the phase 3 HARMONY trial. METHODS: This subgroup analysis included patients with PDD or DLB from HARMONY, a previously completed, multicenter, randomized, discontinuation study of pimavanserin for dementia-related psychosis. Patients with moderate to severe psychosis received pimavanserin 34 mg once daily for 12 weeks (open-label treatment). Those who achieved a sustained response at weeks 8 and 12 were randomized to continue treatment with pimavanserin or discontinue treatment and receive placebo for up to 26 weeks in the double-blind period. The primary endpoint was the time to psychosis relapse as defined by prespecified criteria. Safety was evaluated by adverse events; effects on motor symptoms and cognitive abilities were also assessed. RESULTS: Overall, 392 patients were enrolled in HARMONY; 49 patients with PDD and 27 patients with DLB were included in the open-label safety analysis, of whom 46 met response criteria and were randomized to receive pimavanserin (n = 22) or placebo (n = 24) during the double-blind period. Psychosis relapse risk was significantly lower with pimavanserin vs. placebo (hazard ratio, 0.031; 95% CI, 0.010-0.103; 2-sided nominal P < 0.0001). Fewer than 50% of patients experienced an adverse event in either treatment period; pimavanserin did not negatively affect motor or cognitive function. CONCLUSIONS: Psychosis relapse risk was significantly lower with pimavanserin vs. placebo in patients with Lewy body dementia. Pimavanserin was also well tolerated and did not worsen motor or cognitive function. Results should be interpreted cautiously since this study is a post hoc analysis of a previous trial that was not originally designed or powered to draw clinical conclusions based on dementia subgroups. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03325556 (registered 18 October 2017).

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig. 2

Fig. 2 Kaplan–Meier Estimation of Time to Relapse Due to Psychosis in Patients With PDD + DLB. a DLB, dementia with Lewy bodies; ITT, intention-to-treat; PDD, Parkinson’s disease dementia. a Double-blind ITT analysis set

A

Time to relapse due to psychosis

Fig. 2 · Panel A

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 2:very low support曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
KM Figure1 个面板

Fig. 3

Fig. 3 Kaplan–Meier Estimation of Time to Discontinuation for any Reason in Patients With PDD + DLB. a DLB, dementia with Lewy bodies; ITT, intention-to-treat; PDD, Parkinson’s disease dementia. a Double-blind ITT analysis set

Fig._3a

Time to Discontinuation for any Reason

Fig. 3 · Panel Fig._3a

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Fig._3a 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme jump
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Disposition of Patients With PDD + DLB: Post Hoc Subgroup Analysis. CGI-I, Clinical Global Impression-Improvement; DLB, dementia with Lewy bodies; ITT, intention-to-treat; PDD, Parkinson’s disease dementia; SAPS–H+D, Scale for the Assessment of Positive Symptoms–Hallucinations + Delusions. a Treatment response was defined as ≥30% reduction in the SAPS–H+D total score and a CGI-I score of much improved (2) or very much improved (1). b Patients met the response criteria at both weeks 8 and 12. c Patients were not eligible for the efficacy analysis because they had not entered the double-blind phase at the time of the interim analysis
非 KM Figure
Fig. 4Fig. 4 ESRS-A Total Change From Double-Blind Baseline for Patients With PDD + DLB. a BL, baseline; DLB, dementia with Lewy bodies; ESRS-A, Extrapyramidal Symptom Rating Scale-Abbreviated; PDD, Parkinson’s disease dementia. a Safety analysis set
非 KM Figure
Fig. 5Fig. 5 MMSE Change From Double-Blind Baseline for Patients With PDD + DLB. a BL, baseline; DLB, dementia with Lewy bodies; MMSE, Mini-Mental State Examination; PDD, Parkinson’s disease dementia. a Safety analysis set
非 KM Figure